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Résumé en
anglais
During the last decade, growing efforts have focused on human papillomavirus
(HPV) detection using liquid hybridization, conventional PCR, and real-time PCR-
based methods to increase the overall proportion of patients participating in
cervical cancer screening procedures. We proposed a new general HPV DNA real-
time PCR on the Mx4000 (Stratagene) and LightCycler (Roche Diagnostics) systems
usable for both cervical scrape specimens and urine samples. A linear range was
obtained from 5 DNA copies to 8 log(10) DNA copies/ml, and intra- and interassay
variations were between 1.8 and 4%. Cervical carcinoma and HPV DNA screening
was performed in 333 individual women referred for gynecological examination at
the university hospitals of Angers and Brest and enrolled in the PapU study. Among
cervical specimens (n = 333), 45% were positive for HPV DNA, with a mean viral
load at 5.00 log/ml (+/- 1.73). Among urine samples (n = 177), 37% were positive
with a significant 50-fold-lower mean viral load (3.77 +/- 1.32 log/ml; P < 0.0001).
Kappa agreement for HPV DNA between cervical and urine specimens was excellent
(93%). Thus, we developed a highly sensitive and quantitative general HPV DNA
real-time PCR method that allows mass screening of patients with HPV infection.
The ongoing longitudinal and prospective multicenter PapU study should give us the
opportunity to validate this method adapted to HPV DNA screening in urine samples
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